

BIOGRAPHICAL SKETCH

NAME William D. Chey, MD	POSITION TITLE Associate Professor of Internal Medicine
-----------------------------	--

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, and include*

INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
University of Pennsylvania	BA	1982	Biology
Emory University School of Medicine	MD	1986	Medicine

PROFESSIONAL EXPERIENCE:

1986-1989:	Resident in Internal Medicine, Emory Affiliated Hospitals, Atlanta, Georgia
1990-1993:	Fellow in Gastroenterology, University of Michigan, Ann Arbor, Michigan
1989-1990:	Senior Associate in Internal Medicine, Juha Kokko, Professor and Chairman of Medicine, Emory University School of Medicine, Atlanta, Georgia
1993-1996:	Lecturer in Internal Medicine, University of Michigan, Ann Arbor, MI
1996-2001:	Assistant Professor, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
2001-2007:	Associate Professor, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
2007-	Professor, Department of Internal Medicine, University of Michigan, Ann Arbor, MI

HONORS:

1978-1981	Dean's List, University of Pennsylvania
1981-1982	Alpha Epsilon Delta Pre-Medical Honor Society
1994-1996	Glaxo Institute for Digestive Health Award for Clinical Research
1995	Award for a top ten abstract submitted to the Department of Internal Medicine's Research Day, University of Michigan Medical Center for "Hyperglycemia blunts the perception of electrical rectal stimulation by effects on central processing of afferent input."
1998	Presidential Poster selection, World Congress of Gastroenterology, Vienna, Austria for "Validation of the 13C-urea blood test for H. pylori infection: A US, multicenter trial"
1999	Astra Merck Fellow Research Award from the American College of Gastroenterology for "Interim analysis of a randomized, controlled trial to assess technical and clinical outcomes of a novel colorectal cancer screening strategy" (project mentor)
2001, 2003, 2005, 2007	Elected to "Best Doctors". Best Doctors, Inc, Aiken, SC
2002	Honored as one of the "Best Doctors in Detroit", Hour Detroit Magazine, September
2003	Selected to the Rome III Committee on Functional GI Disorders –Design of Treatment Trials Committee
2003	Award for "Excellence in Teaching" from 2003 University of Michigan GI fellowship class
2003	Michigan Chapter American College of Physicians – "Governor's Award" for service to the MI Chapter
2004, 2005	Rewarded for teaching excellence – Department of Internal Medicine, University of Michigan Internal Medicine Residency Program
2005	Award for "Excellence in Mentorship" from 2005 University of Michigan GI fellowship class
2006	Named as one of "America's Top Physicians"
2007	Marquis Who's Who in America 2007

SELECTED PEER REVIEWED PUBLICATIONS:

1. **Chey WD**, Carpenter S, Spybrook M, Nostrant T, Elta G, Scheiman J. Prolonged effect of omeprazole on the 14C-urea breath test. *Am J Gastroenterol* 91:89-92, 1996.
2. Scheiman JM, **Chey WD**, Behler EM, Crause I, Elta GH. One week therapy for *H. pylori*: A randomized trial of two treatment regimens. *J Clin Gastroenterol* 23:170-3, 1996.
3. **Chey WD**, Fey D, Woods M, Scheiman J, DelValle J, Nostrant T. Lansoprazole and ranitidine effect the accuracy of the 14C-urea breath test by a pH dependent mechanism. *Am J Gastroenterol* 92:446-50, 1997.

4. **Chey WD**, Fisher L, Elta GH, Barnett J, Nostrant T, DelValle J, Scheiman J. Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for *H. pylori* infection: a randomized trial. *Am J Gastroenterol* 92:1483-6, 1997.
5. **Chey WD**, Murthy U, Linscheer W, Barish C, Riff R, Rubin H, Safdi M, Schwartz H, Shah H, Wruble L, El-Zamaity, HMT. The ChemTrak Hp Chek™ fingerstick, whole blood serology test for the detection of *H. pylori* infection. *Am J Gastroenterol* 93:16-19, 1998.
6. **Chey WD**, Fisher L, Barnett J, Delvalle J, Elta GH, Nostrant T, Palaniappan J, Scheiman J. Triple therapy with low versus high dose azithromycin to treat *H. pylori* infection. *Aliment Pharmacol Ther* 12:1263-7, 1998.
7. Fendrick AM, **Chey WD**, Fennerty MB. Estimating the demand for *H. pylori* confirmatory testing after eradication treatment. *Am J Med* 107:133-6, 1999.
8. **Chey WD**, Murthy U, Shaw S, Zawadski A, Linscheer W, Laine L. A comparison of 3 fingerstick, whole blood antibody tests for *H. pylori* infection: a US multi-center trial. *Am J Gastroenterol* 94:1512-5, 1999.
9. **Chey WD**, Murthy U, Toskes P, Carpenter S, Laine L. The 13C-urea blood test accurately detects active *H. pylori* infection: a US, multicenter trial. *Am J Gastroenterol* 94:1522-4, 1999.
10. Mao HV, Lak BV, Long T, Chung NQ, Thang DM, Hop TV, Chien NN, Hoan PQ, Henley KS, Connor BA, Stone CD, **Chey WD**. Omeprazole or ranitidine bismuth citrate with clarithromycin and amoxicillin for 10 days to treat *H. pylori* infection: A randomized, controlled trial in Vietnamese patients with duodenal ulcer. *Aliment Pharmacol Ther* 14:97-101, 2000.
11. **Chey WD**, Metz DC, Shaw S, Kearney D, Montague J, Murthy U. Appropriate timing of the ¹⁴C-Urea breath test to establish eradication of *H. pylori* infection. *Am J Gastroenterol* 95:1171-4, 2000.
12. Stern MA, Fendrick AM, McDonnell WM, Gunaratnam N, Moseley RH, **Chey WD**. A randomized, controlled trial to assess a novel colorectal cancer screening strategy: the conversion strategy. *Am J Gastroenterol* 95:2074-9, 2000.
13. Ladabaum U, Minoshima S, Hasler WL, Cross D, **Chey WD**, Owyang C. Localization of human cortical and subcortical responses to gastric distention using positron emission tomography. *Gastroenterology* 120:369-76, 2001.
14. **Chey WD**, Shapiro B, Zawadski A, Goodman K. Gastric emptying characteristics of a novel ¹³C-octanoate-labelled muffin meal. *J Clin Gastroenterol* 32:394-99, 2001.
15. **Chey WD**, Chathadi K, Montague J, Ahmed F, Murthy U. Intra-gastric acidification reduces the occurrence of false negative urea breath test results in patients taking a proton pump inhibitor. *Am J Gastroenterol* 96:1028-32, 2001.
16. **Chey WD**, Fendrick M. Non-invasive *H. pylori* testing for the test and treat strategy: a decision analysis to assess the impact of past infection on test choice. *Arch Intern Med* 161:2129-32, 2001.
17. Gonlachanvit S, **Chey WD**, Goodman KJ, Parkman HP. Effect of meal size and test duration on gastric emptying and gastric myoelectrical activity as determined with simultaneous EGG and ¹³C-octanoate breath test in normal subjects using a muffin meal. *Dig Dis Sci* 46:2643-50, 2001.
18. Bjornsson E, Hasler WL **Chey WD**, Hooper F, Woods M, Owyang C. Impaired gastrocolonic response and peristaltic reflex in idiopathic constipation: role of 5-HT₃ pathways. *Am J Physiol* 275:G498-505, 1998.
19. Ladabaum U, **Chey WD**, Scheiman J, Fendrick M. Empiric therapy may be cost-effective compared to *H. pylori* testing and treatment in some populations with uninvestigated dyspepsia. *Aliment Pharmacol Ther* 16:1491-1501, 2002.
20. **Chey WD**, Olden K, Carter E, Boyle J, Drossman D, Chang L. Utility of the Rome I and Rome II criteria for IBS in US women. *Am J Gastroenterol* 97:2803-11, 2002.
21. Cash BD, Schoenfeld P, **Chey WD**. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. *Am J Gastroenterol* 97:2812-19, 2002.
22. Brown WH, **Chey WD**, Elta GH. Number of Responses on a Review of Systems Questionnaire Predicts the Diagnosis of Functional GI Disorders. *J Clin Gastroenterol* 36:2222-27, 2003.
23. **Chey WD**, Huang B, Lukasik N, Jackson RL. Lansoprazole vs. Esomeprazole in symptomatic gastro-oesophageal reflux disease: A double-blind, randomized, multicentre trial in 3000 patients confirms comparable symptom relief. *Clin Drug Invest* 23:69-84, 2003.
24. Schoenfeld P, **Chey WD**. An evidence based approach to clinical practice guidelines – diagnosis and treatment of Irritable Bowel Syndrome. *Clinical Gastroenterol Hepatol* 1:322-7, 2003.
25. Cash BD, **Chey WD**. Irritable Bowel Syndrome: A systematic review. *Family Medicine Clinics of North America* 6:647-70, 2004.
26. **Chey WD**, Chey WY, Heath AT, Dukes GE, Carter EG, Northcutt A, Ameen VZ. Long-term efficacy and safety of Alosetron in women with severe diarrhea-predominant Irritable Bowel Syndrome. *Am J Gastroenterol* 99:2195-2203, 2004.

27. Fischer R, Thistle J, Lembo A, Novick J, O'Kane P, **Chey WD**, Beglinger C, Rueegg P, Shi V, Dogra A, Luo D, Earnest D. Tegaserod does not alter fasting or meal-induced biliary tract motility. *Am J Gastroenterol* 99:1342-9, 2004.
28. **Chey WD**. Erosive esophagitis and NERD: Can we really classify patients with heartburn using endoscopic findings? *Clinical Gastroenterol Hepatol* 2:654-5, 2004
29. Johanson JF, Wald A, Tougas G, **Chey WD**, Novick J, Lembo A, Fordham F, Guella M, Nault B. Tegaserod is effective and well tolerated in patients with chronic constipation: Findings from a randomized, double-blind, placebo-controlled trial. *Clin Gastroenterol and Hepatol* 2:796-805, 2004.
30. Saad R, **Chey WD**. A clinician's guide to the diagnosis and treatment of *H. pylori*. *Clev Clin J Med* 72:109-126, 2005.
31. Gonlachanvit S, Rhee J, Sun WM, **Chey WD**. Effect of acute acoustic stress on anorectal function and sensation in healthy humans. *Neurogastroenterol Motil* 17:222-8, 2005.
32. **Chey WD**, Inadomi JM, Booher A, Sharma VK, Fendrick AM, Howden CW. Primary care physicians perceptions and practices on the management of GERD: Results of a national survey, *Am J Gastroenterol* 100:1243-50; 2005.
33. **Chey WD**, Cash BD. Cilansetron: A new serotonergic agent for the irritable bowel syndrome and diarrhea. *Expert Opin Invest Drugs*, 14:185-93;2005.
34. Chang L, **Chey WD**, Harris L, Olden K, Surawicz C, Schoenfeld P. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. *Am J Gastroenterol*, in press.
35. Dickman R, Green C, **Chey WD**, Jones MP, Eisen GM, Ramirez F, Briseno M, Garewal HS, Fass R. Clinical predictors of Barrett's esophagus length, in preparation. *Gastrointestinal Endoscopy*, in press.
36. Saad R, Schoenfeld P, **Chey WD**. Levofloxacin triple or PPI quadruple salvage therapy for persistent *Helicobacter pylori* infection: Results of a meta-analysis. *Am J Gastroenterol*, in press.
37. Ahmet F, **Chey WD**, Murthy U. Evaluation of the Ez-HBT *Helicobacter* blood test to establish *Helicobacter pylori* eradication, *Aliment Pharm Ther*, 22:875-80, 2005.
38. Dickman R, Green C, **Chey WD**, Jones MP, Eisen GM, Ramirez F, Briseno M, Garewal HS, Fass R. Clinical predictors of Barrett's esophagus length. *Gastrointestinal Endoscopy*, 62:675-81, 2005.
39. Saad R, **Chey WD**. What is the most effective treatment for patients with dyspepsia who are negative for *Helicobacter pylori* infection? *Nature Clinical Practice Gastroenterology & Hepatology*, 3:20-21, 2006.
40. **Chey WD**, Eswaran S, Howden CW, Inadomi J, Fendrick AM, Scheiman J. Primary care physicians perceptions of NSAID and aspirin-associated toxicity: Results of a national survey. *Aliment Pharm Ther*, 23:655-68, 2006.
41. Saad R, **Chey WD**. Tegaserod in the treatment of irritable bowel syndrome with constipation. *Women's Health*, 2: 29-42, 2006.
42. Saad R, Schoenfeld P, **Chey WD**. Levofloxacin triple or PPI quadruple salvage therapy for persistent *Helicobacter pylori* infection: Results of a meta-analysis. *Am J Gastroenterol*, 101:488-96, 2006.
40. Chang L, **Chey WD**, Harris L, Olden K, Surawicz C, Schoenfeld P. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. *Am J Gastroenterol*, 101:1-11; 2006.
41. Longstreth G, Thompson WG, **Chey WD**, Houghton L, Mearin F, Spiller R. RomeIII: Functional Bowel Disorders. *Gastroenterology*, 130:1480-91, 2006.
42. Irvine EJ, Whitehead W, **Chey WD**, Matsueda K, Shaw M, Talley NJ, Veldehuyzen van Zanten S. Rome III: Design of treatment trials. *Gastroenterol*, 130:1538-51, 2006.
43. Saad R, **Chey WD**. Current and emerging therapies for functional dyspepsia. *Aliment Pharmacol Ther*, 24;475-92, 2006.
44. Saad R, **Chey WD**. Treatment of *H. pylori* infection in 2006. *Gastroenterol Hepatol Annual Review*, 1:30-35, 2006.

Research Support

Ongoing Research Support

1. GCRC for "Pilot feasibility study of structure-function relationships in pediatric fecal incontinence"
Principal Investigator: Cheryl Garipey, MD
Co-investigators: WD Chey, B Felt, P Strouse
Funding period: 11/01/05-4/30/07 (\$26,108)
2. Salix for "A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 3 different doses of rifaximin bid for 2 or 4 weeks in the treatment of patients with IBS-D"

Principal Investigator: WD Chey, MD

Co-investigators: R Saad, MD

Funding period: 5/1/06-1/31/09 (\$44,075)

3. Alizyme for "A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study of renzapride in women with constipation-predominant IBS"
Principal Investigator: WD Chey, MD
Co-investigators: R Saad, MD
Funding period: 3/20/06-10/30/07 (\$63,302)
4. Alizyme for "A phase III, multicenter, open label, extension study to evaluate the long-term safety of renzapride in women with constipation-predominant IBS"
Principal Investigator: WD Chey, MD
Co-investigators: R Saad, MD
Funding period: 7/6/06-8/30/08 (\$43,704)
5. Novartis for "The effects of tegaserod on orocecal transit in elderly patients with chronic constipation"
Principal Investigator: WD Chey, MD
Co-investigators: H Parkman, I Bottoli, D Joseph
Funding period: 7/1/06-6/30/07 (\$750,000 for 3 sites - \$244,000 to UM)
6. Trine Pharmaceuticals for "A randomized, double-blind placebo controlled study to assess the safety and efficacy of TRN-002 for the symptomatic treatment of diarrhea-predominant IBS in females"
Principle Investigator: WD Chey, MD
Co-Investigators: R. Saad MD, D Brenner, MD
Funding period: 10/16/06-10/31/07 (\$33,064)
7. Prometheus Laboratories for "The value of diagnostic testing in Irritable Bowel Syndrome"
Principal Investigator: WD Chey, MD
Co-Investigators: B Cash
Funding period 9/12/2003-12/30/2007 (\$31,265)
8. Janssen Pharmaceuticals for "Nonerosive Reflux Disease: A study to understand etiology and predictors of response to PPI therapy"
Principal Investigator: WD Chey, MD
Co-investigators: M Cleary, M Shaw, J Inadomi
Funding period: 2/1/02-4/30/07 (\$80,579)
9. Janssen Pharmaceuticals for "Esophageal Sensation in Patients with Heartburn: Correlation of Esophageal Sensation with Response to PPI"
Principal Investigator: WD Chey, MD
Co-investigators: J Rubenstein, B Nojkov
Funding period: 2/1/04-1/31/08 (\$52,948)
10. TAP for "NSAID and aspirin utilization amongst US primary care physicians: A follow-up survey"
Principal Investigator: WD Chey, MD
Funding period: 4/27/06-4/26/07 (\$18,649)

Selected Completed Research Support

1. Novartis for "A randomized, double-blind, placebo controlled multi-center study to assess the efficacy, safety, and tolerability of tegaserod 2 mg bid and 6 mg bid given orally vs. placebo in patients with chronic constipation"
Principal Investigator: WD Chey, MD
Co-Investigators: C Owyang, G Elta, J Barnett
Funding period: 5/1/01-11/1/02
Project description: This industry initiated study attempts to evaluate the effect of tegaserod on clinical outcomes in patients with chronic constipation.
2. Forest Laboratories for "Safety and efficacy of dexloxyglumide in female patients with constipation-predominant irritable bowel syndrome"
Principal Investigator: WD Chey, MD
Co-Investigators: C Owyang, G Elta
Funding period: 2/1/02-3/31/03

Project description: This industry initiated study attempts to evaluate the effectiveness of a novel CCK antagonist in patients with constipation-predominant irritable bowel syndrome.

3. Vela Pharmaceuticals for "A double-blind randomized, placebo-controlled study of R-Tofisopam in outpatients with Irritable Bowel Syndrome"
Principal Investigator: WD Chey, MD
Co-Investigators: C Owyang, WL Hasler, J Wiley
Funding period 9/9/2003-6/30/2004 (\$50,133)
4. Phase I SBIR for "A novel diagnostic test for irritable bowel syndrome"
Principal Investigator: D Wagner, PhD
Co-investigators: WD Chey
Funding period: 3/1/03-2/28/05 (\$27,394)
5. Novartis for "A 6 week randomized, double-blind, double-dummy placebo controlled, multicenter study to assess the effect of tegaserod 2mg TID on dyspeptic symptoms in diabetic patients with symptoms of diabetic gastropathy"
Principal Investigator: WD Chey, MD
Co-investigators: C Owyang, WL Hasler, J Wiley, L Fisher
Funding period: 2/25/04-6/30/2005 (\$57,486)
6. Novartis Pharmaceuticals for "A 4-week, multicenter, double-blind, placebo-controlled, randomized, parallel-group, clinical study to evaluate the efficacy of tegaserod in relieving the symptoms of female patients with IBS, excluding those with predominant diarrhea IBS"
Principal Investigator: WD Chey, MD
Co-investigators: C Owyang, WL Hasler, J Wiley, L Fisher
Funding period: 1/11/04-7/31/05 (\$30,517)
7. Trine Pharmaceuticals for "A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of TRN-002 for the symptomatic treatment of diarrhea-predominant irritable bowel syndrome"
Principal Investigator: WD Chey, MD
Co-investigators: C Owyang, WL Hasler, J Wiley, L Fisher
Funding period: 12/1/04-11/30/2005 (\$40,679)
8. Smart Pill Diagnostics for "Medical Utilization in patients with gastroparesis"
Principal Investigator: WD Chey, MD
Co-investigators: John Wo
Funding period: 11/1/04-10/31/2005 (\$25,389)
9. Smart Pill Diagnostics for "A comparison of ACT GI Monitoring system with scintigraphic gastric emptying procedure for determining gastric residence time"
Principal Investigator: WD Chey, MD
Co-investigators: Braden Kuo, Micheal Sitrin, Henry Parkman, Kenneth Koch
Funding period: 2/1/05-8/31/2005 (\$TBA)
10. Rome Foundation for Disorders of GI Function for "Validation of the Rome III modular questionnaire"
Principal Investigator: WD Chey, MD
Co-investigators: R Saad, MD
Funding period: 10/1/05-4/31/2006 (\$7,500)
11. Sucampo Pharmaceuticals for "A 12 week, multicenter, double-blind, randomized efficacy and safety study of lubiprostone for the treatment of constipation-predominant irritable bowel syndrome"
Principal Investigator: WD Chey, MD
Co-investigators: R Saad, MD
Funding period: 10/1/05-12/31/2006 (\$50,079)
12. Sucampo Pharmaceuticals for "An open-label study of lubiprostone for constipation-predominant irritable bowel syndrome"
Principal Investigator: WD Chey, MD
Co-investigators: R Saad, MD
Funding period: 1/1/06-3/31/2007 (\$52,614)